HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ECHA Pursues Fees From Misclassified REACH Registrants

This article was originally published in The Rose Sheet

Executive Summary

Registrants who have misclassified their entity size in order to pay smaller registration fees under Europe’s REACH chemicals program are being asked to submit new registrations or appeal to the agency’s Board of Appeal within three months, according to a Nov. 16 release from the agency.

You may also be interested in...



ECHA Decision On REACH Dossier Annulled On Registrant Appeal

ECHA must reevaluate a REACH registration dossier from German chemical firm Thor GmbH following a review by the ECHA Appeals Board, which determined that the agency did not clearly communicate to the registrant an important deadline in the decision-making process.

NGOs Launch “One-Stop Shop” For Chemical Info, Seeking Safer Markets

SafeMarkets.org is the result of collaboration between public-health and environmental NGOs to raise consumer awareness, and provides industry with a one-stop shop for data and alternatives on controversial chemicals, according to groups involved. Campaign for Safe Cosmetics co-founder Stacy Malkan discussed the project in an Aug. 27 interview.

ECHA Targets Registration Errors As REACH Deadline Looms

With the next REACH deadline in sight, ECHA announces that it is taking action against registrants that falsely register substances as intermediates. The agency also is making a final push to identify lead registrants for unclaimed substances and offering improved IT to help support the development of quality dossiers.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018385

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel